Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation

Piotr Chodór; Krzysztof Wilczek; Łukasz Włoch; Roman Przybylski; Jan Głowacki; Tomasz Kukulski; Tomasz Niklewski; Marian Zembala; Zbigniew Gąsior; Zbigniew Kalarus

doi:10.5114/aic.2019.83497

Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation

Piotr Chodór ¹

,

Krzysztof Wilczek ²

,

Łukasz Włoch ¹

,

Roman Przybylski ³

,

Jan Głowacki ⁴

,

Tomasz Kukulski ¹

,

Tomasz Niklewski ³

,

Marian Zembala ³

,

Zbigniew Gąsior ²

,

Zbigniew Kalarus ¹

Department of Cardiology, Congenital Heart Diseases and Electrotherapy, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland
3rd Department of Cardiology, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland
Department of Cardiac Surgery and Transplantology, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland
Diagnostic Department, Department of Radiology, Silesian Center for Heart Diseases, Medical University of Silesia, Zabrze, Poland

Adv Interv Cardiol 2019; 15, 2 (56): 167–175

DOI: https://doi.org/10.5114/aic.2019.83497

Online publish date: 2019/06/26

View full text

AMA

Chodór P, Wilczek K, Włoch Ł, et al. Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2019:167-175. doi:10.5114/aic.2019.83497.

APA

Chodór, P., Wilczek, K., Włoch, Ł., Przybylski, R., Głowacki, J., & Kukulski, T. et al. (2019). Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 167-175. https://doi.org/10.5114/aic.2019.83497

Chicago

Chodór, Piotr, Krzysztof Wilczek, Łukasz Włoch, Roman Przybylski, Jan Głowacki, Tomasz Kukulski, and Tomasz Niklewski et al. 2019. "Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation". Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej: 167-175. doi:10.5114/aic.2019.83497.

Harvard

Chodór, P., Wilczek, K., Włoch, Ł., Przybylski, R., Głowacki, J., Kukulski, T., Niklewski, T., Zembala, M., Gąsior, Z., and Kalarus, Z. (2019). Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, pp.167-175. https://doi.org/10.5114/aic.2019.83497

MLA

Chodór, Piotr et al. "Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation." Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej, 2019, pp. 167-175. doi:10.5114/aic.2019.83497.

Vancouver

Chodór P, Wilczek K, Włoch Ł, Przybylski R, Głowacki J, Kukulski T et al. Impact of Coronary Artery Disease on the Outcomes of Severe Aortic Stenosis Treatment Treated with Transcatheter Aortic Valve Implantation. Advances in Interventional Cardiology/Postępy w Kardiologii Interwencyjnej. 2019:167-175. doi:10.5114/aic.2019.83497.

Introduction

The presence of coronary artery disease (CAD) in patients who underwent transcatheter aortic valve implantation (TAVI) may increase in-hospital and long-term mortality.

Aim

To evaluate the impact of CAD in patients who underwent TAVI.

Material and methods

The study group consisted of the first 142 patients treated with TAVI between 26 November 2008 and 31 December 2015. The patients were divided into two groups: group I comprised 103 (72.5%) patients with CAD, and group II comprised 39 (27.5%) patients without CAD.

Results

Group I was characterized by a significantly higher risk according to EuroSCORE – 11.2 ±2.5 vs. 9 ±2.3 in group II (p < 0.001) and Logistic EuroSCORE – 25.4 ±13.4 vs. 16.3 ±8.7 (p < 0.001). 30-day mortality was 8 (7.8%) vs. 2 (5.1%) (p = NS) and 1-year mortality was 22 (21.4%) vs. 6 (15.4%) (p = NS) in group I and II respectively. The composite endpoint evaluating the efficacy of TAVI was achieved in 82 (79.6%) vs. 31 (79.5%) (p = NS) in group I and II respectively. The composite endpoint, which involved 30-day observation, occurred in 39 (37.86%) vs. 12 (30.77%) (p = NS) and the composite endpoint, which involved 1-year evaluation of the clinical efficacy of TAVI, occurred in 48 (57.8%) vs. 13 (48.1%) (p = NS) in patients with and without CAD respectively.

Conclusions

The short- and mid-term outcomes of TAVI patients with CAD, despite higher risk profile, did not differ from the outcomes of treatment in patients without CAD.

Keywords

percutaneous coronary intervention, coronary artery disease, coronary artery bypass graft, transcatheter aortic valve implantation

Share

Indexed in

Integrated with

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications